This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetics of Fondaparinux in Patients With Major Orthopedic Surgery (POP-A-RIX)

This study has been completed.
Information provided by:
Centre Hospitalier Universitaire de Saint Etienne Identifier:
First received: February 4, 2010
Last updated: NA
Last verified: February 2010
History: No changes posted
Fondaparinux is a synthetic antithrombotic agent with specific anti-factor Xa activity. A population pharmacokinetic model of fondaparinux, based on data obtained in patients included in phase II/III trials, has been described. However, the validity of this model in everyday practice needed to be confirmed. This study was a multicenter, prospective cohort study in consecutive orthopedic patients treated with 2.5 mg of fondaparinux. Anti-Xa activities were recorded in 809 patients. Population parameters and inter-individual variability were estimated using NONMEM VI software. A two-compartment model with first-order absorption best described fondaparinux pharmacokinetics. Covariates partly explaining inter-individual variability were body weight, age and creatinine clearance estimated by the simplified Modification of Diet in Renal Disease formula. A body weight less than 50 kg and moderate renal failure increased drug exposure. These results suggest that fondaparinux pharmacokinetics need to be confirmed in patient populations not fully assessed in phase II/III studies

Orthopedic Surgery

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Population Pharmacokinetics of Fondaparinux Administered at Prophylactic Doses After Major Orthopedic Surgery in Everyday Practice

Resource links provided by NLM:

Further study details as provided by Centre Hospitalier Universitaire de Saint Etienne:

Primary Outcome Measures:
  • To determine an anti-Xa activity value which is predicted of a haemorrhage risk [ Time Frame: day 9 ]

Biospecimen Retention:   Samples Without DNA
blood sample for anti-Xaactivity measure

Enrollment: 997
Study Start Date: September 2004
Study Completion Date: February 2007
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
patients with blood sample
Patients with major orthopedic surgery and prophylactic doses of fondaparinux who have 3 blood sample during their hospitalization to measure anti-Xa activity


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with major orthopedic surgery who need prophylactic doses of fondaprinux

Inclusion Criteria:

  • patient who need leg major orthopedic surgery
  • age > 18 years
  • patient who need prophylactic doses of fondaparinux

Exclusion Criteria:

  • contra-indication to fondaparinux
  • renal insufficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01063543

CHARRET Françoise
Annonay, France, 07100
Caen, France, 14000
Paris, France, 75679
PETIT Pierre-Yves
Pierre Bénite, France, 69495
BARRE Jeanne
Reims, France, 51092
MAITRE Anne-Marie
Rouen, France, 76031
Saint-etienne, France, 42013
Saint-etienne, France, 42100
Sponsors and Collaborators
Centre Hospitalier Universitaire de Saint Etienne
Principal Investigator: Patrick MISMETTI, Pr CHU SAINT-ETIENNE
  More Information

Responsible Party: Pr Patrick MISMETTI, Centre Hospitalier Universitaire de Saint Etienne Identifier: NCT01063543     History of Changes
Other Study ID Numbers: 0601069
Study First Received: February 4, 2010
Last Updated: February 4, 2010

Keywords provided by Centre Hospitalier Universitaire de Saint Etienne:
orthopedic surgery
patients with major orthopedic surgery

Additional relevant MeSH terms:
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017